// App-Quantinova.ai

3640 : Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.

Researchers

Presenter

  • Cornelis J. A. Punt

Principal Investigators

  • Lieke H Simkens

  • Johan Van Rooijen

  • Agnes W Van de Wouw

  • Olaf Loosveld

  • Geert-Jan Creemers

  • Mathijs P Hendriks

  • Maartje Los

  • Robbert Jeroen Van Alphen

  • Marco Polee

  • Erik W Muller

  • Ankie Van Der Velden

  • Thymen Van Voorthuizen

  • Miriam Koopman

  • Linda Mol

  • Johannes J Kwakman

  • Erik D. van Werkhoven

Medical Centers

  • Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

  • Maxima Medical Center, Eindhoven, Netherlands

  • Martini Hospital Groningen, Groningen, Netherlands

  • Viecuri Medical Centre, Venlo, Netherlands

  • Amphia hospital, Breda, Netherlands

  • Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands

  • Medical Center Alkmaar, Alkmaar, Netherlands

  • St Antonius Hospital, Nieuwegein, Netherlands

  • TweeSteden Ziekenhuis, Dongen, Netherlands

  • Medical Center Leeuwarden, Leeuwarden, Netherlands

  • Slingeland Hospital, Doetinchem, Netherlands

  • Department of Medical Oncology, Tergooi Hospital, Hilversum, Netherlands

  • Rijnstate Ziekenhuis, Arnhem, Netherlands

  • Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

  • Netherlands Comprehensive Cancer Organization, Nijmegen, Netherlands

  • Academic Medical Center, Amsterdam, Netherlands

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • Circulating tumor cells

  • Lactate dehydrogenase

Drug/Treatment

  • Capecitabine

  • Bevacizumab

Outcome

  • Unknown

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01918852

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved